Companies
(73)
AAC Clyde Space
ALM Equity
Alzinova
Arion Bank
Arlandastad Group
Ascelia Pharma
Bactiguard
Bergman & Beving
Besqab
BioPorto
Björn Borg
Bokusgruppen
Bonava
BTS Group
Byggmästaren
CAG Group
Calviks
Carasent
CDON
Clavister
Clemondo Group
eEducation Albert
Elanders
Elicera Therapeutics
Eolus
Ependion
EQL Pharma
Faron Pharmaceuticals
FluoGuide
Gentoo Media
GiG Software
HAKI Safety
HANZA
Iconovo
Idun Industrier
InfraCom
Initiator Pharma
Intervacc
ITAB Group
Kebni
Lifecare ASA
Lindex Group
Logistri
Lumi Education Group
Lytix Biopharma
Medivir
Mentice
Micro Systemation
MilDef Group
Net Insight
Nordic LEVEL Group
Orexo
Ortoma
OssDsign
Paxman
Pierce
PowerCell
Pricer
Qualisys
Relais Group
SaltX
Scanfil
Sensys Gatso Group
Sleep Cycle
Solar Foods
Spago Nanomedical
Svedbergs Group
Taaleri
Terranor
Vertiseit
Vivesto
W5 Solutions
Waystream
Sweden
Healthcare
Near term
6-12 MONTHS
While we believe the valuation is supported by the revenue stream from Becton Dickinson (BD) related to the Foley catheter alone, the Zimmer Biomet agreement has clearly underperformed our expectations. Although we believe the share price could react positively to news regarding expanded BD sales in new geographies, in our view, Bactiguard must prove there is broader commercial value for its coating technology by signing new partners and show success outside the Foley catheter space. Zimmer Biomet’s launch in Europe remains slow and limited to just a small part of the total trauma assortment, and the agreement has recently been narrowed with Bactiguard regaining US rights. Signing new licence deals should be positive for sentiment, but we doubt investors would start discounting large future revenue until such products are launched and sales take off.
Long term
6+ YEARS
Bactiguard has a proven coating technology for preventing infection, and a base business generating stable annual revenue from its licence agreement with Becton Dickinson. Having taken a step back to basics and focusing on licensing the coating technology to larger medtech companies instead of developing its own product, Bactiguard’s cost base is lower, meaning there is large operating leverage if it succeeds in broadening the use of the coating technology.
Bactiguard’s ability to find the right licensing partners and its potential to roll out products with the coating technology.
The slow start to Zimmer Biomet’s launch of orthopaedic trauma products in Europe and uncertain pathway to get products approved in the US.
Track record of not delivering on long-term financial targets.
Price
Fair range high value
Fair range low value
The lower end of our fair value range is based on a peer multiples approach, combining a forward-looking 2026e EV/sales multiple and a 2028e EV/EBITDA multiple. The higher end of our fair value range is based on our DCF model, applying a WACC of 7%.
We value Bactiguard using a combination of a DCF model and peer multiples (EV/sales and EV/EBITDA). The lower end of our fair value range is based on a peer valuation model scenario where EBITDA in 2028e falls shy of our base-case estimate. The higher end of our fair value range is derived from a DCF model value based on WACC of 7%. Specifically, in our peer based valuation we apply a blend of forward-looking EV/sales and EV/EBITDA multiples – 2026e EV/sales multiple alongside a 2028e EV/EBITDA, which we believe captures both our view of the near-term revenue performance and medium-term earnings potential.
About DNB Carnegie Access
DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.
Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.
Private Banking
Tailored wealth management. Your financial future, personalized.
Montrose
A digital investment platform designed for passionate investors.
DNB Carnegie
Leading Nordic investment bank and wealth management.
© Copyright DNB Carnegie Investment Bank AB